Posted by Michael Wonder on 03 Jun 2019
Novartis shows growing strength in lung cancer innovation with new capmatinib investigational data
3 June 2019 - The U.S. FDA recently granted capmatinib breakthrough therapy designation for the treatment of patients with metastatic NSCLC harbouring MET exon-14 skipping mutation with disease progression on or after platinum-based chemotherapy; discussions with global health authorities are underway.
Novartis announced today new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from the GEOMETRY mono-1 Phase II clinical trial demonstrating that investigational MET inhibitor capmatinib (INC280) shows promise as a potential treatment option for patients with locally advanced or metastatic NSCLC that harbor MET exon-14 skipping mutation.
